• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊曲康唑的毒代动力学:对治疗药物监测的意义。

Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.

作者信息

Lestner Jodi M, Roberts Steven A, Moore Caroline B, Howard Susan J, Denning David W, Hope William W

机构信息

The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.

出版信息

Clin Infect Dis. 2009 Sep 15;49(6):928-30. doi: 10.1086/605499.

DOI:10.1086/605499
PMID:19681707
Abstract

We explored concentration-toxicity relationships for itraconazole among 216 patients. Logistic regression revealed a progressive increase in the probability of toxicity with increasing concentrations of itraconazole. Classification and regression tree analysis suggested that 17.1 mg/L of itraconazole (measured using a bioassay) was the concentration level at which the population of patients was separated into 2 groups, each with a high and a low probability of toxicity.

摘要

我们在216名患者中探究了伊曲康唑的浓度-毒性关系。逻辑回归显示,随着伊曲康唑浓度的增加,毒性发生概率呈逐步上升趋势。分类与回归树分析表明,伊曲康唑浓度为17.1 mg/L(采用生物测定法测量)时,患者群体被分为两组,每组发生毒性的概率有高有低。

相似文献

1
Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.伊曲康唑的毒代动力学:对治疗药物监测的意义。
Clin Infect Dis. 2009 Sep 15;49(6):928-30. doi: 10.1086/605499.
2
Tremor: a newly described adverse event with long-term itraconazole therapy.震颤:长期应用伊曲康唑治疗后新出现的不良反应。
J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):327-9. doi: 10.1136/jnnp.2009.174706.
3
A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.伊曲康唑治疗变应性支气管肺曲霉病的随机试验。
N Engl J Med. 2000 Mar 16;342(11):756-62. doi: 10.1056/NEJM200003163421102.
4
[Prolonged therapeutic response to voriconazole in a case of allergic bronchopulmonary aspergillosis].[伏立康唑对一例变应性支气管肺曲霉病的长期治疗反应]
Arch Bronconeumol. 2007 Jan;43(1):49-51.
5
[Prevention of aspergillosis with itraconazole in neutropenic patients: importance of drug monitoring].
Bull Acad Natl Med. 1999;183(2):371-80; discussion 380-1.
6
[Level of evidence for therapeutic drug monitoring of itraconazole].
Therapie. 2011 Mar-Apr;66(2):103-8. doi: 10.2515/therapie/2011015. Epub 2011 Jun 6.
7
A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis.一种采用荧光检测的快速高效液相色谱法,用于测定患有变应性支气管肺曲霉病的囊性纤维化儿童血浆中伊曲康唑和羟基伊曲康唑的浓度。
Biomed Chromatogr. 2006 Apr;20(4):343-8. doi: 10.1002/bmc.569.
8
Severe asthma with fungal sensitization in a child: response to itraconazole therapy.儿童真菌致敏性严重哮喘:伊曲康唑治疗的反应。
Pediatrics. 2010 May;125(5):e1255-8. doi: 10.1542/peds.2009-2443. Epub 2010 Apr 12.
9
[Example of active therapeutic follow-up: itraconazole].
Therapie. 1996 Sep-Oct;51(5):502-6.
10
A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis.伊曲康唑脉冲疗法与特比萘芬治疗念珠菌性 toenail 甲真菌病的初步评估。 (注:这里“toenail”结合语境可能是指“趾甲”,整体翻译可能稍显生硬,原英文表述也存在一定的不规范,推测是关于用伊曲康唑脉冲疗法和特比萘芬治疗念珠菌性趾甲甲真菌病的初步评估研究类内容。)
Int J Dermatol. 2005 Sep;44(9):785-8. doi: 10.1111/j.1365-4632.2004.02117.x.

引用本文的文献

1
The Impact of Dietary Interventions on the Pharmacokinetics of Antifungal Drugs: A Systematic Review with Meta-analyses.饮食干预对抗真菌药物药代动力学的影响:一项系统评价与荟萃分析
Clin Pharmacokinet. 2025 May 10. doi: 10.1007/s40262-025-01511-6.
2
Isavuconazole therapeutic drug monitoring and association with adverse events.艾沙康唑治疗药物监测及其与不良事件的关联。
J Antimicrob Chemother. 2025 Apr 28;80(6):1702-6. doi: 10.1093/jac/dkaf128.
3
Therapeutic Drug Monitoring of Antimicrobial Drugs in Children with Cancer: A New Tool for Personalized Medicine.
癌症患儿抗菌药物的治疗药物监测:个性化医疗的新工具。
Paediatr Drugs. 2025 Jan;27(1):41-56. doi: 10.1007/s40272-024-00663-5. Epub 2024 Nov 6.
4
Controversies in the clinical management of chronic pulmonary aspergillosis.慢性肺曲霉病临床管理中的争议
Breathe (Sheff). 2024 Oct 1;20(3):230234. doi: 10.1183/20734735.0234-2023. eCollection 2024 Oct.
5
Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.革新神经治疗学:研究药物重新利用策略。
CNS Neurol Disord Drug Targets. 2025;24(2):115-131. doi: 10.2174/0118715273329531240911075309.
6
Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids.评估奥替康唑和其他两种四氮唑类抗真菌药抑制肾上腺类固醇生成及皮质类固醇外周代谢的潜在风险。
Front Pharmacol. 2024 Aug 8;15:1394846. doi: 10.3389/fphar.2024.1394846. eCollection 2024.
7
Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation.抗真菌药物再利用:纳米晶体制剂给药后伊曲康唑和羟基伊曲康唑的群体药代动力学。
J Antimicrob Chemother. 2023 May 3;78(5):1219-1224. doi: 10.1093/jac/dkad072.
8
Blastomycosis: A Review of Mycological and Clinical Aspects.芽生菌病:真菌学与临床方面综述
J Fungi (Basel). 2023 Jan 14;9(1):117. doi: 10.3390/jof9010117.
9
Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis.超生物利用度伊曲康唑与传统伊曲康唑在不同剂量治疗皮肤癣菌病时的药代动力学及临床比较
Drugs Context. 2023 Jan 9;12. doi: 10.7573/dic.2022-8-1. eCollection 2023.
10
Update on the Epidemiology, Diagnosis, and Treatment of Coccidioidomycosis.球孢子菌病的流行病学、诊断与治疗进展
J Fungi (Basel). 2022 Jun 25;8(7):666. doi: 10.3390/jof8070666.